Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis
Modulation of NF-κB, p53 and Bcl-2 in apoptosis induced by cisplatin in HeLa cells
Introduction
Apoptosis is an active cell death process. Morphologically, it is characterized by condensation of nuclear chromatin and cytoplasm, and formation of membrane-enclosed apoptotic bodies, containing well-preserved organelles. The biochemical hallmark of apoptosis is the formation of distinct DNA fragments of oligonucleosomal size (180–200 bp) 1, 2. The process is active and requires specific gene regulation. A critical role for p53 in the execution of some forms of apoptosis has been suggested 3, 4, 5, 6, 7. This protein is a sequence-specific DNA-binding protein, active as a transcription factor. It has been proposed that p53 may be involved in the cellular response to DNA damage, producing arrest in the G1 phase of the cell cycle to allow efficient repair of the DNA before entry to S phase, or cell death if the damage is too large to be repaired [3]. Cells containing negligible amounts of wild-type p53 protein as a result of specific degradation induced by infection with human papillomavirus, or cells expressing mutant p53, are not able to arrest the cell cycle progression and continue to proliferate, leading to genetic instability and eventually malignancy [4]. Another gene implicated in apoptosis is Bcl-2 [8]. The Bcl-2 gene product functions as an anti-apoptotic signal, suppressing apoptosis induced by a wide variety of stimuli, including chemotherapeutic drugs and γ radiation 9, 10. The exact mechanism of Bcl-2 in preventing apoptosis is still not clear. However, Bcl-2 has been implicated in cellular control of their redox state11, 12.
Apoptosis plays a role in a number of disease processes, including cancer. It has been suggested that antineoplastic drugs may exert their effects by inducing apoptotic cell death. In this regard cisplatin (CDDP) has been shown to induce apoptosis in diverse cell lines 13, 14, 15. The drug is an effective crosslinking agent that generates: intra- and inter-strand DNA crosslinks, DNA–protein crosslinks, cisplatin–DNA–glutathione crosslinks and DNA-monoadducts [16]. The mechanism of CDDP cell toxicity has not been completely elucidated although inhibition of DNA synthesis, synthesis of specific mRNA and generation of active oxygen species have been considered critical for its toxicity 17, 18, 19, 20. A central role for reactive oxygen species (ROI) in cell death has been proposed 21, 22; therefore, the transcriptional factors NF-κB and AP-1, both implicated in the oxidative stress response, could play a role in the apoptotic process.
Recently, we have demonstrated that exposure of HeLa cells to CDDP induces apoptosis. After 18 h of treatment with the drug, these cells undergo specific DNA fragmentation [14]. We investigated the DNA binding activity of the transcriptional factors NF-κB and AP-1 upon CDDP treatment, since they might be implicated in the oxidative stress response [22]and the apoptotic process elicited by this drug 19, 20. We also analyzed the distribution of p53, which is activated by NF-κB [23]and is involved in the apoptotic process in several cell lines. Finally, since Bcl-2 protein has been widely related to cell death and is down-regulated by p53 we also analyzed its expression [24].
Section snippets
Cell culture
Human HeLa cells were maintained as monolayers in DMEM containing 10% (v/v) fetal bovine serum and incubated at 37°C in a humidified atmosphere of a 5% (v/v) CO2 in air. Cells at 70% confluence were treated with 40 μM CDDP. DMEM and fetal bovine serum were obtained from Gibco; CDDP and other chemicals were obtained from Sigma.
Immunoblotting
At the times shown, monolayers were washed twice with PBS to eliminate dead cells. Cell extracts of CDDP-treated cells were prepared by lysis with Laemmli buffer [25].
Results
As previously reported [14], exposure of HeLa cells to CDDP resulted in a time and dose-dependent apoptosis, as stated by morphological features, extensive and specific DNA fragmentation and in situ end-labeling of DNA breaks. To determine whether the treatments with CDDP (40 μM) have any effect in the NF-κB and AP-1 transcriptional factors, we performed electrophoretic mobility shift assays with nuclear extracts prepared from control or treated cells exposed to CDDP for the indicated times.
Discussion
Since the events that lead to the apoptotic cell death following exposure to DNA-damaging agents are not clearly defined, we analyzed the participation of two of the most important nuclear regulators, AP-1 and NF-κB, in apoptotic process in HeLa cells exposed to CDDP. AP-1 binding activity was not modified, excluding a direct participation of this transcriptional complex in the apoptotic process, although it is possible that other specific complexes not detected by the probe could be
Acknowledgements
This work was supported in part by CONACYT REF: F383 and M9304 infrastructure grants.
References (53)
- et al.
The Bcl-2 family of proteins: regulators of cell death and survival
Trends Cell. Biol.
(1994) - et al.
Bcl-2 oncogene protects a bone marrow-derived pre-B cell line from 5′-fluor, 2′-deoxyuridine-induced apoptosis
Biochem. Biophys. Res. Commun.
(1993) - et al.
Bcl-2 functions in an antioxidant pathway to prevent apoptosis
Cell
(1993) - et al.
Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia
Biochem. Pharmacol.
(1990) - et al.
Cisplatin induces apoptosis in a human ovarian carcinoma cell line without concomitant internucleosomal degradation of DNA
Exp. Cell. Res.
(1994) - et al.
Cisplatin generates superoxide anion by interaction with DNA in a cell-free system
Biochem. Biophys. Res. Commun.
(1994) - et al.
Viral, worm and radical implications for apoptosis
Trends Biochem. Sc.
(1994) - et al.
NF-κB activation of p53
J. Biol. Chem.
(1994) - et al.
A modified micro-Bradford procedure for elimination of interference from sodium dodecyl sulfate, other detergents and lipids
Anal. Biochem.
(1994) - et al.
DNA Binding of purified transcription factor NF-κB
J. Biol. Chem.
(1991)